Professor Yi Miao, as the chairman of the conference and the director of Pancreas Center of the First Affiliated Hospital of Nanjing Medical University, explained the connotation of the conference theme "Sharing for Better Care" at the opening ceremony, 'Sharing is a joy, sharing is a taste, Sharing is a concept and sharing is a realm. The purpose of this conference is to build an international platform for the sharing and exchange of cutting-edge knowledge, emerging technologies and the latest ideas for domestic and foreign pancreatic scholars. Benefit our patients and improve their lives.' The conference set up an interdisciplinary international exchange platform. This conference is the first global academic conference in this field hosted in China. The conference used full English lectures, discussions, simultaneous interpretation and webcasting to provide doctors and scholars at home and abroad with the most direct communication platform with the top experts. The webcast of the conference involved more than 10,000 clicks. Participants from all over the world had an in-depth discussion on the hot issues of clinical diagnosis and treatment of pancreatic tumors, acute and chronic pancreatitis, and basic research.
At this conference, Professor Markus W. Büchler from the University of Heidelberg, Germany, Professor Castillo from Harvard University, Professor Wolfgang from Johns Hopkins University, Professor Takaori from Kyoto University, Japan, and Professor Yi Miao from Nanjing Medical University, jointly signed the International "Pancreas Center Talent Training Alliance" program. The establishment of the alliance aims to provide young pancreatic specialists, especially pancreatic surgeons with a multinational joint training platform, provide them with joint scientific research, continuing education programs, and academic community support. It is an international and interdisciplinary channels for communication.
Throughout the academic agenda of the conference, many Chinese pancreatic centers showed China's clinical experience and scientific research results in recent years, and it was a resounding voice on the international academic stage for the domestic pancreatic disease community.
Markus W. Büchler
Executive Director and Professor of Surgery, University of Heidelberg, Germany
Many doctors around the world have diagnosed advanced pancreatic cancer as "unresectable". In fact, it is not "unresectable" but "I cannot remove" pancreatic cancer.
Christopher L. Wolfgang
Chief, Division of Hepatobiliary and Pancreatic Surgery, Professor of Surgery, Pathology and Oncology, Johns Hopkins Hospital, USA
It is not the tumor that we remove, but the thing that remains in the patient's body that causes the recurrence of pancreatic cancer after surgery.
Executive Director and Professor of Surgery, University of Heidelberg, Germany
Many doctors around the world have diagnosed advanced pancreatic cancer as "unresectable". In fact, it is not "unresectable" but "I cannot remove" pancreatic cancer.
Christopher L. Wolfgang
Chief, Division of Hepatobiliary and Pancreatic Surgery, Professor of Surgery, Pathology and Oncology, Johns Hopkins Hospital, USA
It is not the tumor that we remove, but the thing that remains in the patient's body that causes the recurrence of pancreatic cancer after surgery.
Christopher L. Wolfgang
Chief, Division of Hepatobiliary and Pancreatic Surgery, Professor of Surgery, Pathology and Oncology, Johns Hopkins Hospital, USA
It is not the tumor that we remove, but the thing that remains in the patient's body that causes the recurrence of pancreatic cancer after surgery.
Chief, Division of Hepatobiliary and Pancreatic Surgery, Professor of Surgery, Pathology and Oncology, Johns Hopkins Hospital, USA
It is not the tumor that we remove, but the thing that remains in the patient's body that causes the recurrence of pancreatic cancer after surgery.
John P. Neoptolemos
Professor of Surgery, University of Heidelberg, Germany
Now in the UK, neoadjuvant treatment of pancreatic cancer is not allowed outside clinical trials. These clinical trials are important because they determine the future lives of these young people before us.
Professor of Surgery, University of Heidelberg, Germany
Now in the UK, neoadjuvant treatment of pancreatic cancer is not allowed outside clinical trials. These clinical trials are important because they determine the future lives of these young people before us.
Carlos Fernández-del Castillo
Director of Pancreas and Biliary Surgery Program, Professor of Surgery, Harvard Medical School, USA
How does pathological status of IPMN positive margin affect the prognosis?
Director of Pancreas and Biliary Surgery Program, Professor of Surgery, Harvard Medical School, USA
How does pathological status of IPMN positive margin affect the prognosis?
Masao Tanaka
Chief Director, Shimonoseki City Hospital, Japan
The examination method and frequency of IPMN follow-up need to be clarified.
Chief Director, Shimonoseki City Hospital, Japan
The examination method and frequency of IPMN follow-up need to be clarified.
Massimo Falconi
Professor of Surgery, Chairman of the Pancreatic Unit at the University Vitae Salute, San Raffaele Hospital, Italy
Even for local excision of pancreatic neuroendocrine tumors, please remove at least one lymph node.
Professor of Surgery, Chairman of the Pancreatic Unit at the University Vitae Salute, San Raffaele Hospital, Italy
Even for local excision of pancreatic neuroendocrine tumors, please remove at least one lymph node.
Jin He
Assistant Professor of Surgery and Oncology, Johns Hopkins Hospital, USA
Hereditary pancreatitis may become the main indication for pancreatic resection plus islet autograft.
Assistant Professor of Surgery and Oncology, Johns Hopkins Hospital, USA
Hereditary pancreatitis may become the main indication for pancreatic resection plus islet autograft.
Tooru Shimosegawa
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan
The development of puncture equipment has significantly improved the accuracy of the histopathological diagnosis of autoimmune pancreatitis guided by EUS-FNA.
Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan
The development of puncture equipment has significantly improved the accuracy of the histopathological diagnosis of autoimmune pancreatitis guided by EUS-FNA.
Ashok k Saluja
Professor and Vice-Chair, Department of Surgery Director, Sylvester Pancreatic Cancer Research Institute Professor of Surgery, University of Miami, USA
Translational research from basic to clinical will enable more new drugs to benefit patients with malignant tumors.
Professor and Vice-Chair, Department of Surgery Director, Sylvester Pancreatic Cancer Research Institute Professor of Surgery, University of Miami, USA
Translational research from basic to clinical will enable more new drugs to benefit patients with malignant tumors.
Jun Yu
Chief Scientist, Division of Hepatobiliary and Pancreas Surgery Assistant Professor, Department of Surgery, Johns Hopkins Hospital, USA
The next-generation sequencing of EUS-FNA puncture specimens will provide a new basis for accurate treatment evaluation for patients with pancreatic cancer.
Chief Scientist, Division of Hepatobiliary and Pancreas Surgery Assistant Professor, Department of Surgery, Johns Hopkins Hospital, USA
The next-generation sequencing of EUS-FNA puncture specimens will provide a new basis for accurate treatment evaluation for patients with pancreatic cancer.
Laura DeLong Wood
Assistant Professor of Surgery, Johns Hopkins Hospital, USA
The level of pancreatic cancer heterogeneity may be an important assessment indicator for predicting tumor progression and recurrence.
Assistant Professor of Surgery, Johns Hopkins Hospital, USA
The level of pancreatic cancer heterogeneity may be an important assessment indicator for predicting tumor progression and recurrence.
Paula Ghaneh
Professor of Surgery, University of Liverpool, England
The efficacy of PET-CT in distinguishing pancreatic cancer from chronic pancreatitis needs to be improved.
Professor of Surgery, University of Liverpool, England
The efficacy of PET-CT in distinguishing pancreatic cancer from chronic pancreatitis needs to be improved.
Herbert J. Zeh
Professor and Chair of Surgery, UT Southwest Medical Center
Autophagy inhibitors can improve the efficacy of adjuvant therapy for pancreatic cancer.
Professor and Chair of Surgery, UT Southwest Medical Center
Autophagy inhibitors can improve the efficacy of adjuvant therapy for pancreatic cancer.
